Amneal Pharmaceuticals (AMRX) Proxy filing summary

Executive summary

• Proposed acquisition of Kashiv BioSciences, LLC aims to create a global biosimilar leader with direct access to over $300B in global biologic LOEs over the next decade.

• Transaction is pending shareholder approval and satisfaction of closing conditions, with regulatory approvals already received in the U.S. and India.

• Integration planning is underway, leveraging a decade-long relationship between the companies.

Voting matters and shareholder proposals

• Shareholders are asked to approve the acquisition of Kashiv BioSciences, LLC, as outlined in the Membership Interest Purchase Agreement dated April 21, 2026.

• Proxy materials have been distributed, and investors are urged to review all documents filed with the SEC.

Board of directors and corporate governance

• Directors and certain executive officers are participating in the proxy solicitation for the proposed transaction.

• Information on director and executive officer interests is detailed in the proxy statement and related SEC filings.